Antibacterial Compounds
The compounds of the present invention are pyrazole[4,3-b]pyridin-6-carboxamide derivatives characterised by direct antibacterial activity against several Gram-positive bacteria
Biomarkers for Diabetes Therapies
The present invention represents an in vitro implementable method and related kit for assessing the response to immune tolerance restoration therapy by evaluating the expression of specific microRNAs (miRNAs) as biomarkers of residual beta-cell function.
Antiviral Compounds and Uses thereof
The invention concers compounds that act directly on the extracellular virus.
Treatment of Alkaptonuria and Tyrosinemia type 1
The invention consists of alternative compounds to nitisinone, for the treatment of both AKU and HT1.
New compounds for the treatment of acute pain
The present invention serves the development of new therapeutic strategies and new non-opioid drugs for the treatment of pain
Therapeutics for Covid-19 patients
The invention concerns the use of DNA aptamers that can shield the SARS-CoV-2 binding site on the cell, and halt the cell-to-cell spreading of coronavirus.
New Dendrimeric Pyrrolidines
The invention proposes a new approach to rare genetic diseases for which no cures are available, only symptomatic treatments through the preparation of novel multivalent molecules active toward the human enzymes responsible for them
Antagonism of B3 adrenoceptor for the treatment of cancer immune tolerance
The invention relates to the use of beta-blocking compounds, in particular the antagonist of ?3 adrenoceptor (?3-ARs), for the treatment of immune-tolerance associated with pathological states, such as cancer.
A_Atrofi: New compounds for the treatment of musculoskeletal atrophy and cachexia
The invention is represented by a mixture of molecules, called A_ATROFI, capable of regulating the balance between protein synthesis and its degradation in skeletal muscle cells.
New activators of SIRT1 enzyme for the treatment of cardiovascular and cardiometabolic pathologies
The present invention targets a class of compounds able to activate the enzyme SIRT1 in humans by regulating numerous metabolic functions. The appropriately designed compounds could be used in pharmaceutical formulations, preferably in the treatment or prevention of cardiometabolic diseases